Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 17.1% on Thursday . The company traded as low as C$0.28 and last traded at C$0.32. 684,632 shares changed hands during trading, an increase of 2% from the average session volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Performance
The business has a fifty day moving average of C$0.15 and a 200-day moving average of C$0.10. The company has a market capitalization of C$27.44 million, a P/E ratio of -15.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- What is Put Option Volume?
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- Short Selling – The Pros and Cons
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
